TY - JOUR
T1 - Impact of Radiofrequency Ablation on Malignant Biliary Strictures
T2 - Results of a Collaborative Registry
AU - Sharaiha, Reem Z.
AU - Sethi, Amrita
AU - Weaver, Kristen R.
AU - Gonda, Tamas A.
AU - Shah, Raj J.
AU - Fukami, Norio
AU - Kedia, Prashant
AU - Kumta, Nikhil A.
AU - Clavo, Carlos M.Rondon
AU - Saunders, Michael D.
AU - Cerecedo-Rodriguez, Jorge
AU - Barojas, Paola Figueroa
AU - Widmer, Jessica L.
AU - Gaidhane, Monica
AU - Brugge, William R.
AU - Kahaleh, Michel
N1 - Funding Information:
Michel Kahaleh MD has received grant support from Boston Scientific, Fujinon, EMcison, Xlumena Inc., W.L. Gore, MaunaKea, Apollo Endosurgery, Cook Endoscopy, ASPIRE Bariatrics, GI Dynamics, and MI Tech. He is a consultant for Boston Scientific and Xlumena Inc.; Amrita Sethi MD is a consultant for Boston Scientific. All other authors have no conflicts of interest to report.
Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/7/13
Y1 - 2015/7/13
N2 - Background: Radiofrequency ablation of malignant biliary strictures has been offered for the last 3 years, but only limited data have been published. Aim: To assess the safety, efficacy, and survival outcomes of patients receiving endoscopic radiofrequency ablation. Methods: Between April 2010 and December 2013, 69 patients with unresectable neoplastic lesions and malignant biliary obstruction underwent 98 radiofrequency ablation sessions with stenting. Results: A total of 69 patients (22 male, aged 66.1 ± 13.3) were included in the registry. The etiology of malignant biliary stricture included unresectable cholangiocarcinoma (n = 45), pancreatic cancer (n = 19), gallbladder cancer (n = 2), gastric cancer (n = 1), and liver metastasis from colon cancer (n = 3). Seventy-eight percentage of patients had prior chemotherapy. All strictures were stented post-radiofrequency ablation with either plastic stents or metal stents. The mean stricture length treated was 14.3 mm. There was a statistically significant improvement in stricture diameter post-ablation (p < 0.0001). The likelihood of stricture improvement was significantly greater in pancreatic cancer-associated strictures [RR 1.8 (95 % 1.03–5.38)]. Seven patients (10 %) had adverse events, not linked directly to radiofrequency ablation. Median survival was 11.46 months (6.2–25 months). Conclusion: Radiofrequency ablation is effective and safe in malignant biliary obstruction and seems to be associated with improved survival.
AB - Background: Radiofrequency ablation of malignant biliary strictures has been offered for the last 3 years, but only limited data have been published. Aim: To assess the safety, efficacy, and survival outcomes of patients receiving endoscopic radiofrequency ablation. Methods: Between April 2010 and December 2013, 69 patients with unresectable neoplastic lesions and malignant biliary obstruction underwent 98 radiofrequency ablation sessions with stenting. Results: A total of 69 patients (22 male, aged 66.1 ± 13.3) were included in the registry. The etiology of malignant biliary stricture included unresectable cholangiocarcinoma (n = 45), pancreatic cancer (n = 19), gallbladder cancer (n = 2), gastric cancer (n = 1), and liver metastasis from colon cancer (n = 3). Seventy-eight percentage of patients had prior chemotherapy. All strictures were stented post-radiofrequency ablation with either plastic stents or metal stents. The mean stricture length treated was 14.3 mm. There was a statistically significant improvement in stricture diameter post-ablation (p < 0.0001). The likelihood of stricture improvement was significantly greater in pancreatic cancer-associated strictures [RR 1.8 (95 % 1.03–5.38)]. Seven patients (10 %) had adverse events, not linked directly to radiofrequency ablation. Median survival was 11.46 months (6.2–25 months). Conclusion: Radiofrequency ablation is effective and safe in malignant biliary obstruction and seems to be associated with improved survival.
KW - Biliary obstruction
KW - Cholangiocarcinoma
KW - Pancreatic cancer
KW - Radiofrequency ablation
KW - Stent patency
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84930819085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930819085&partnerID=8YFLogxK
U2 - 10.1007/s10620-015-3558-3
DO - 10.1007/s10620-015-3558-3
M3 - Article
C2 - 25701319
AN - SCOPUS:84930819085
SN - 0163-2116
VL - 60
SP - 2164
EP - 2169
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 7
ER -